Abstract: Abstract: Objective To study the status of acute myocardial infarction (AMI) during the epidemic of coronavirus disease 2019 (COVID-19). Methods This study was a cross-sectional study of the same period. The AMI treated in Tianjin Chest Hospital from January 20 to February 20, 2019 was used as the control group (non-COVID-19 epidemic period group: 314 patients). The AMI treated during the COVID-19 epidemic period from January 20 to February 20, 2020 was the observation group (COVID-19 epidemic group: 133 cases). The indicators including clinical outcome (all-cause mortality), the ratio of AMI receiving reperfusion treatment within 24 hours, the time from onset to the first medical contact (FMC), the time from door to balloon (D-to-B), and total ischemic time were compared between two groups. Results The all-cause mortality during hospitalization was significantly higher in the COVID-19 epidemic group than that in the nonepidemic group (14.3% vs. 1.6%, P＜0.01). There was no significant difference in the proportion of reperfusion treatment within 24 hours between the two groups (46.6% vs. 40.6%, P＞0.05). The FMC time was significantly delayed in the COVID- 19 epidemic group compared with that of the non-COVID-19 epidemic group (P＜0.01). In the STEMI population, the Dto-B time and the total ischemic time were longer in the COVID-19 epidemic group than those in the non-epidemic group (P＜0.01). Conclusion During the epidemic of COVID-19, the patient's consultation time was delayed, the in-hospital emergency time was prolonged and the all-cause mortality in hospital was significantly increased. Based on the principles of COVID-19 prevention and control, the AMI treatment process should be optimized to restore normal medical order as soon as possible.

Key words: myocardial infarction, coronavirus disease 2019, reperfusion, treatment outcome, mortality